Resolvin D5 

Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis^[1][2][3].

Resolvin D5 (100, 500 nM; 3-5 days) suppresses Th17 cell differentiation and facilitates Treg differentiation in CD4⁺ T cells isolated from SKG mouse spleens in a concentration-dependent manner^[1].
Resolvin D5 (1-100 nM; 3 days) suppresses the proliferation of CD4+ T cells isolated from SKG mouse spleens in a concentration-dependent manner, with 100 nM inducing a significant reduction in proliferating cells^[1].
Resolvin D5 (10-500 nM; 3 days) suppresses RANKL-induced osteoclast differentiation in bone marrow-derived macrophages from SKG mice in a concentration-dependent manner, with 10, 100, and 500 nM concentrations reducing TRAP+ MNC formation and downregulating key osteoclastogenesis-related genes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Resolvin D5 (1000 ng; i.p.; daily) does not prevent arthritis progression in a chronic persistent SKG mouse model of rheumatoid arthritis^[1].
Resolvin D5 (100 ng; i.t.; single dose) produces a transient, male-specific reduction in chemotherapy-induced mechanical allodynia in wild-type, Trpv1 knockout, and Trpa1 knockout mice, with no analgesic effect in female mice^[2].
Resolvin D5 (10 ng; i.t.; single dose) produces a male-specific reduction in formalin-induced Phase II inflammatory pain, with no analgesic effect in female mice or on Phase I pain responses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

360.49

C₂₂H₃₂O₄

578008-43-2

Liquid

Colorless to light yellow

CC/C=C\C[C@H](O)/C=C/C=C\C/C=C\C=C\[C@@H](O)C/C=C\CCC(O)=O

Shipping with dry ice.

-80°C

• [1]. Yamada H, et al. Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis. Sci Rep. 2021;11(1):17312. Published 2021 Aug 27.  [Content Brief]

  [2]. Luo X, et al. Resolvin D5 Inhibits Neuropathic and Inflammatory Pain in Male But Not Female Mice: Distinct Actions of D-Series Resolvins in Chemotherapy-Induced Peripheral Neuropathy. Front Pharmacol. 2019;10:745. Published 2019 Jul 5.  [Content Brief]

  [3]. Chun HW, et al. Resolvin D5, a Lipid Mediator, Inhibits Production of Interleukin-6 and CCL5 Via the ERK-NF-κB Signaling Pathway in Lipopolysaccharide-Stimulated THP-1 Cells. J Microbiol Biotechnol. 2020;30(1):85-92.  [Content Brief]